Venish SR
✅ Mood stabilization
✅ Anxiety reduction
✅ Improved concentration
✅ Enhanced energy levels
✅ Depression management
Venish SR contains Venlafaxine.
✓ Ιατρικά ελεγμένο από Morgan Ellis — Ερευνητής Φαρμακευτικής · 8 χρόνια εμπειρία · Τελευταία αναθεώρηση: Μάιος 2026
⚡ Quick Answer — What is Venish SR?
Venish SR περιέχει venlafaxine ER (37.5 / 75 / 150 mg ER) from a WHO-GMP certified manufacturer (Healing Pharma) — an SNRI with broad evidence in depression and anxiety-spectrum disorders. Standard start: 75 mg once daily with food; titrate to 150–225 mg/day for full SNRI activity (max 375 mg in MDD, 225 mg in GAD/social anxiety/panic). Onset: 2–4 weeks. Below 150 mg the drug behaves mostly as an SSRI; norepinephrine reuptake inhibition appears at higher doses. Important: dose-dependent blood-pressure rise (BP must be monitored at > 225 mg). Has a severe discontinuation syndrome — mandatory taper. More dangerous in overdose than SSRIs (cardiac toxicity, seizures).
📦 Κάθε παραγγελία καλύπτεται από την Πολιτική Εγγύησης Επαναποστολής — εάν το δέμα σας δεν φτάσει εντός 20 εργάσιμων ημερών, το επαναποστέλλουμε.
Γιατί να παραγγείλετε από τη MedsBase
Τα γενόσημα φάρμακά μας προέρχονται από κατασκευαστές που πιστοποιούνται από την WHO-GMP και αποστέλλονται παγκοσμίως σε διακριτική, απλή συσκευασία — χωρίς όνομα φαρμάκου στο εξωτερικό του δέματος. Οι πληρωμές με κάρτα δρομολογούνται μέσω ρυθμισμένου επεξεργαστή (οι περιγραφές εκκαθάρισης περιλαμβάνουν ρυθμισμένο επεξεργαστή πληρωμών με κάρτα — ποτέ “MedsBase” ή οποιοδήποτε όνομα φαρμάκου). Γίνονται δεκτές και πληρωμές με κρυπτονομίσματα και τραπεζική μεταφορά SEPA. Κάθε παραγγελία καλύπτεται από την Πολιτική Επαναποστολής Εξασφαλίσεώς μας.
What Is Venish SR?
Venish SR is an oral extended-release tablet/capsule of venlafaxine (37.5 / 75 / 150 mg ER) manufactured by Healing Pharma under WHO-GMP certification. Venlafaxine (US brand Effexor XR) is the prototype serotonin-norepinephrine reuptake inhibitor (SNRI). It blocks both the serotonin transporter (SERT) at lower doses and the norepinephrine transporter (NET) at higher doses, producing a dose-dependent shift from SSRI-like to SNRI-like pharmacology.
It is a first-line option in NICE and APA guidelines for major depression and is one of the most-evidenced antidepressants for generalised anxiety disorder.
Εγκεκριμένες Ενδείξεις
- Major depressive disorder (MDD) — including treatment-resistant depression at higher doses
- Generalised anxiety disorder (GAD)
- Social anxiety disorder (chronic / generalised)
- Panic disorder — with and without agoraphobia
- Off-label: diabetic neuropathy, chronic fatigue, fibromyalgia, vasomotor symptoms of menopause
Χορήγηση
| Ενδείξεις | Start | Typical effective range | Μέγιστο | Σημειώσεις |
|---|---|---|---|---|
| MDD | 75 mg/day with food | 150–225 mg/day | 375 mg/day | Increase by 75 mg every 2 weeks |
| GAD, social anxiety, panic | 37.5–75 mg/day | 75–225 mg/day | 225 mg/day | Slower up-titration in panic to avoid early agitation |
| Elderly / hepatic / renal impairment | 37.5 mg/day | Up to 75–150 mg with caution | — | Reduce by 25–50% in moderate hepatic impairment |
Mechanism by Dose
Pharmacology shifts as dose climbs
| Daily dose | Pharmacology | Clinical relevance |
|---|---|---|
| 37.5–75 mg | Predominantly serotonergic (SSRI-like) | Useful as a starting / sub-therapeutic dose for tolerability |
| 75–150 mg | Mostly serotonergic with emerging noradrenergic activity | Lower end of antidepressant efficacy range |
| 150–225 mg | Combined SERT + NET inhibition (true SNRI) | Standard effective dose for most adults; full SNRI benefit |
| 225–375 mg (MDD only) | Strong SERT + NET inhibition | Used in treatment-resistant depression; BP and cardiac monitoring required |
Παρενέργειες
Common, persistent, and rare side effects
| Συχνότητα | Αποτέλεσμα | Notes / management |
|---|---|---|
| Συχνά | Nausea (dose-dependent) | Take with food; usually subsides over 1–2 weeks |
| Συχνά | Headache, dizziness | Transient; adequate hydration |
| Συχνά | Insomnia or somnolence | Often dose in the morning if activating |
| Συχνά | Dry mouth, constipation, sweating | Sweating may persist; can be marked |
| Συχνά | Sexual dysfunction | Similar prevalence to SSRIs |
| Less common | Increased blood pressure (dose-dependent) | Check BP at baseline and periodically; significant rise above 225 mg/day in 5–10% — may need dose reduction or switch |
| Less common | Increased pulse, palpitations | Caution in patients with cardiac disease |
| Less common | Weight changes (modest) | Less weight gain than paroxetine or mirtazapine |
| Σπάνιες | Hyponatraemia (SIADH) | Older adults at greatest risk |
| Σπάνιες | Bleeding risk | Caution with NSAIDs, anticoagulants |
| Σπάνιες | Serotonin syndrome | See interactions |
| Σπάνιες | Mydriasis / acute angle-closure glaucoma | Caution in narrow-angle glaucoma |
Discontinuation Syndrome
Venlafaxine has a short half-life (parent ~5 h; active metabolite desvenlafaxine ~11 h). Discontinuation symptoms are severe and rapid, second only to paroxetine: brain zaps, dizziness, nausea, sweating, irritability, insomnia, vivid dreams, flu-like aches. Often appear within 24–48 hours of a missed dose.
Mandatory slow taper: reduce by 75 mg every 2–4 weeks; below 75 mg use the smallest available capsule and consider every-other-day or hyperbolic tapering. Never stop abruptly. Patients on long-term venlafaxine often spend months on tapering — this is normal.
Αλληλεπιδράσεις Φαρμάκων
Absolute contraindications: MAOIs, linezolid, methylene blue. 14-day washout.
Serotonergic interactions: triptans, tramadol, pethidine, dextromethorphan, St John’s wort, lithium — serotonin syndrome risk.
CYP2D6 substrate: levels rise with strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine). Consider dose reduction.
Bleeding risk: NSAIDs, aspirin, warfarin, DOACs.
Cardiac and Overdose Considerations
Venlafaxine is more dangerous in overdose than SSRIs: cardiac conduction abnormalities, QT prolongation, seizures, and serotonin syndrome have been reported. Provide only short supplies to patients at acute suicide risk. Pre-existing significant cardiac disease, recent MI, or uncontrolled hypertension are relative contraindications.
Συχνές Ερωτήσεις
How long does Venish SR take to work?
Anxiety symptoms often improve in 2–3 weeks; mood response in MDD typically appears at 4–6 weeks. Patients on sub-therapeutic doses (< 150 mg) may need dose escalation before seeing full benefit.
Why does the dose matter so much for venlafaxine?
Below 150 mg/day, venlafaxine acts mostly like an SSRI — norepinephrine reuptake inhibition appears only at higher doses. Patients who don’t respond at 75 mg often respond once titrated to 150 mg or above.
Will Venish SR raise my blood pressure?
Possibly — venlafaxine causes dose-dependent BP increases. Below 150 mg the effect is small; above 225 mg, 5–10% of patients see clinically significant increases. BP should be monitored at baseline and after dose escalations.
Can I stop Venish SR abruptly?
No — venlafaxine has one of the worst discontinuation syndromes in the antidepressant class (brain zaps, dizziness, nausea, sweating). Mandatory taper, often over months for long-term users.
Is Venish SR safe in pregnancy?
Limited data — not the first-choice antidepressant in pregnancy. Sertraline is preferred. Late-third-trimester exposure carries a small risk of neonatal adaptation syndrome and persistent pulmonary hypertension of the newborn.
Does Venish SR cause weight gain?
Less than paroxetine or mirtazapine. Some patients see modest weight changes; others lose weight from initial GI side effects. Less metabolic burden than antipsychotics.
Can I drink alcohol on Venish SR?
Light, occasional alcohol is generally tolerated. Heavy alcohol use worsens depression / anxiety, increases sedation, and is implicated in disinhibited behaviour.
Τι συμβαίνει αν χάσω μια δόση;
Take it as soon as you remember unless close to the next dose. Withdrawal symptoms can begin within 24–48 hours of a missed dose — do not skip multiple doses.
How is Venish SR different from duloxetine or desvenlafaxine?
All are SNRIs. Duloxetine has a different binding profile (more SNRI even at lower doses, hepatic concerns), is also approved for diabetic neuropathy and fibromyalgia. Desvenlafaxine is the active metabolite of venlafaxine — bypasses CYP2D6 metabolism, more predictable plasma levels.
How should Venish SR be stored?
Store at 15–30 °C in the original blister packaging, away from moisture and sunlight. Keep out of reach of children — venlafaxine overdose is medically significant.
Σχετικές Εναλλακτικές
Άλλα προϊόντα σε Χρόνιες Παθήσεις που οι πελάτες εξετάζουν επίσης:
More options in Situational Anxiety Treatment
Ταξινομημένα σύμφωνα με τον όγκο παραγγελιών στο MedsBase — τι επιλέγουν άλλοι πελάτες σε αυτήν την κατηγορία.
| Ισχύς | 37.5 mg |
|---|---|
| Ποσότητα | 30 δισκία, 60 δισκία, 90 δισκία, 180 δισκία |
Venish SR
Ερωτήσεις & Απαντήσεις
Venish SR
Σχετικά προϊόντα
Κριτικές
Δεν υπάρχουν ακόμη κριτικές